AP901A - Eprosartan dihydrate and a process for its production and formulation. - Google Patents

Eprosartan dihydrate and a process for its production and formulation. Download PDF

Info

Publication number
AP901A
AP901A APAP/P/1997/000956A AP9700956A AP901A AP 901 A AP901 A AP 901A AP 9700956 A AP9700956 A AP 9700956A AP 901 A AP901 A AP 901A
Authority
AP
ARIPO
Prior art keywords
compound
pharmaceutical composition
compound according
diuretic
blocker
Prior art date
Application number
APAP/P/1997/000956A
Other languages
English (en)
Other versions
AP9700956A0 (en
Inventor
Nageswara R Palepu
Godapi M Venkatesh
Sarma Duddu
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21765344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP901(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AP9700956A0 publication Critical patent/AP9700956A0/xx
Application granted granted Critical
Publication of AP901A publication Critical patent/AP901A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
APAP/P/1997/000956A 1996-03-29 1997-03-27 Eprosartan dihydrate and a process for its production and formulation. AP901A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1441496P 1996-03-29 1996-03-29

Publications (2)

Publication Number Publication Date
AP9700956A0 AP9700956A0 (en) 1997-04-30
AP901A true AP901A (en) 2000-11-23

Family

ID=21765344

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/000956A AP901A (en) 1996-03-29 1997-03-27 Eprosartan dihydrate and a process for its production and formulation.

Country Status (36)

Country Link
EP (1) EP0889880B1 (ja)
JP (1) JP4316013B2 (ja)
CN (2) CN1214682A (ja)
AP (1) AP901A (ja)
AR (1) AR006439A1 (ja)
AT (1) ATE239723T1 (ja)
AU (1) AU726694B2 (ja)
BG (1) BG64095B1 (ja)
BR (1) BR9708336A (ja)
CA (1) CA2250395C (ja)
CZ (1) CZ293345B6 (ja)
DE (1) DE69721749T2 (ja)
DK (1) DK0889880T3 (ja)
DZ (1) DZ2199A1 (ja)
EA (1) EA001958B1 (ja)
EG (1) EG23889A (ja)
ES (1) ES2198564T3 (ja)
HK (1) HK1016594A1 (ja)
HU (1) HU228263B1 (ja)
ID (1) ID16507A (ja)
IL (1) IL126319A0 (ja)
MA (1) MA24437A1 (ja)
MY (1) MY117682A (ja)
NO (2) NO311760B1 (ja)
NZ (1) NZ332008A (ja)
OA (1) OA11176A (ja)
PL (1) PL188816B1 (ja)
PT (1) PT889880E (ja)
RO (1) RO118870B1 (ja)
SK (1) SK282346B6 (ja)
TR (1) TR199801954T2 (ja)
TW (1) TW434239B (ja)
UA (1) UA49880C2 (ja)
UY (1) UY24504A1 (ja)
WO (1) WO1997036874A1 (ja)
ZA (1) ZA972686B (ja)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69807695T2 (de) * 1997-06-27 2003-07-31 Smithkline Beecham Corp., Philadelphia Eprosartan-monohydrate
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
TR200001412T2 (tr) * 1997-11-17 2000-09-21 Smithkline Beecham Corporation Çok miktarda ilaç içeren, derhal ve modifike bir salgılama sağlayan oral doz formülasyonları ve bunların imal edilmesi için proses.
BR9908474A (pt) 1998-03-04 2000-12-05 Takeda Chemical Industries Ltd Preparação de liberação prolongada, processo para a produção de uma preparação de liberação prolongada, e, composição farmacêutica
ZA991922B (en) * 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
CA2338256C (en) * 1998-07-20 2008-09-23 Smithkline Beecham Corporation Bioenhanced formulations comprising eprosartan in oral solid dosage form
GB9820405D0 (en) 1998-09-18 1998-11-11 Smithkline Beecham Plc Process
AU1157500A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Medicaments based on combinations of lacidipine and telmisartan or of physiological derivatives thereof
WO2000027397A1 (en) * 1998-11-06 2000-05-18 Glaxo Group Limited Antihypertensive medicaments containing lacidipine and telmisartan
PL196895B1 (pl) * 1999-04-28 2008-02-29 Takeda Pharmaceutical Zastosowanie związku o aktywności antagonistycznej angiotensyny II lub jego soli do wytwarzania kompozycji farmaceutycznej do leczenia lub hamowania rozwoju retynopatii prostej lub retynopatii przed-proliferacyjnej
GB9920917D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
RU2298418C2 (ru) * 2000-04-12 2007-05-10 Новартис Аг Комбинация по меньшей мере двух соединений, выбранных из групп антагонистов at1-рецептора или ингибиторов асе (ангиотензинпревращающий фермент), или ингибиторов hmg-coa-редуктазы (бета-гидрокси-бета-метилглутарил-кофермент-а-редуктаза)
AU2002364381A1 (en) * 2001-11-23 2003-06-10 Solvay Pharmaceuticals Gmbh Hypertonia treatment during the acute phase of a cerebrovascular accident
KR100517638B1 (ko) 2002-04-08 2005-09-28 주식회사 엘지생명과학 게미플록사신 산염의 새로운 제조방법
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
CN1662256A (zh) * 2002-05-17 2005-08-31 诺瓦提斯公司 用于心肌梗死二级预防的血管紧张素Ⅱ受体阻断剂和β－阻断剂的组合
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
EP3045174A1 (en) 2003-01-31 2016-07-20 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
EP2181109A4 (en) 2007-07-25 2011-08-03 Hetero Drugs Ltd CRYSTALLINE PARTICLES OF EPROSARTAN MESYLATE AND PROCESS FOR PREPARING PURE EPROSARTAN
WO2009084028A2 (en) * 2007-12-03 2009-07-09 Neuland Laboratories Ltd Improved process for manufacturing anhydrous (e)-3-[2-butyl-1- {(4-carboxyphenyl) methyl}-1h-imidazole-5-yl]-(thiophen-2- ylmethyl)prop-2-enoic acid methane sulfonate
CN101333216A (zh) 2008-08-03 2008-12-31 浙江华海药业股份有限公司 一种新的依普罗沙坦甲磺酸盐成盐工艺
CN113354553B (zh) * 2021-06-03 2023-09-15 北京宝诺康医药科技有限公司 一种甲氧氯普胺单盐酸盐一水合物的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312828A (en) * 1989-06-14 1994-05-17 Finkelstein Joseph A Substituted imidazoles having angiotensin II receptor blocking activity
DE69133019T2 (de) * 1990-12-14 2002-11-28 Smithkline Beecham Corp., Philadelphia Imidazolyl-alkencarbonsäuren

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists

Also Published As

Publication number Publication date
BR9708336A (pt) 1999-08-03
PL188816B1 (pl) 2005-04-29
ZA972686B (en) 1997-09-29
TW434239B (en) 2001-05-16
DK0889880T3 (da) 2003-09-01
UA49880C2 (uk) 2002-10-15
SK282346B6 (sk) 2002-01-07
OA11176A (en) 2003-05-13
CA2250395A1 (en) 1997-10-09
DE69721749T2 (de) 2004-03-25
AP9700956A0 (en) 1997-04-30
MA24437A1 (fr) 1998-10-01
SK132298A3 (en) 1999-03-12
AR006439A1 (es) 1999-08-25
TR199801954T2 (xx) 1998-12-21
BG64095B1 (bg) 2003-12-31
CN1214682A (zh) 1999-04-21
HUP9902769A2 (hu) 2000-03-28
CN1332167A (zh) 2002-01-23
BG102822A (en) 1999-11-30
JP4316013B2 (ja) 2009-08-19
HUP9902769A3 (en) 2000-04-28
PL329046A1 (en) 1999-03-01
EP0889880A1 (en) 1999-01-13
HU228263B1 (en) 2013-02-28
JP2000508632A (ja) 2000-07-11
AU726694B2 (en) 2000-11-16
UY24504A1 (es) 1997-09-19
ATE239723T1 (de) 2003-05-15
WO1997036874A1 (en) 1997-10-09
EP0889880A4 (en) 1999-06-23
DZ2199A1 (fr) 2002-12-03
EA001958B1 (ru) 2001-10-22
IL126319A0 (en) 1999-05-09
ID16507A (id) 1997-10-02
NO984503D0 (no) 1998-09-28
CA2250395C (en) 2005-09-06
AU2547097A (en) 1997-10-22
NZ332008A (en) 1999-05-28
PT889880E (pt) 2003-09-30
DE69721749D1 (de) 2003-06-12
EA199800873A1 (ru) 1999-02-25
ES2198564T3 (es) 2004-02-01
HK1016594A1 (en) 1999-11-05
NO2002005I1 (no) 2002-09-02
MY117682A (en) 2004-07-31
EG23889A (en) 2007-12-12
NO311760B1 (no) 2002-01-21
EP0889880B1 (en) 2003-05-07
CZ293345B6 (cs) 2004-04-14
CZ310198A3 (cs) 1999-03-17
NO984503L (no) 1998-09-28
RO118870B1 (ro) 2003-12-30

Similar Documents

Publication Publication Date Title
AP901A (en) Eprosartan dihydrate and a process for its production and formulation.
US6558699B2 (en) High drug load immediate and modified release oral dosage formulations and processes for their manufacture
US6517871B1 (en) Bioenhanced formulations comprising eprosartan in oral solid dosage form
US6630498B2 (en) Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation
CA2310028C (en) High drug load immediate and modified release oral dosage formulations and processes for their manufacture
US6420412B2 (en) Eprosartan dihydate and a process for its production and formulation
CA2294515C (en) Eprosartan monohydrate
CA2299470C (en) Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation
KR100477295B1 (ko) 에프로사르탄이수화물,그의제조방법및조성물